Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
企業コードXGN
会社名Exagen Inc
上場日Sep 19, 2019
最高経営責任者「CEO」Mr. John Aballi
従業員数203
証券種類Ordinary Share
決算期末Sep 19
本社所在地1261 Liberty Way
都市VISTA
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号92081
電話番号17605601501
ウェブサイトhttps://exagen.com/
企業コードXGN
上場日Sep 19, 2019
最高経営責任者「CEO」Mr. John Aballi
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし